1 Medicinal Organic Chemistry Group, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal. 2 BioISI - Biosystems and Integrative Sciences Institute, Faculty of Sciences, Universidade de Lisboa, Campo Grande, C8 building, 1749-016 Lisboa, Portugal
Ms. Israa Mohamad Alakhras Aljnadi
1 Medicinal Organic Chemistry Group, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal. 2 BioISI - Biosystems and Integrative Sciences Institute, Faculty of Sciences, Universidade de Lisboa, Campo Grande, C8 building, 1749-016 Lisboa, Portugal
Organic small molecules that can recognize and bind to G-quadruplex and i-Motif nucleic acids have great potential as selective drugs or as tools in drug target discovery programs, or even in the development of nanodevices for medical diagnosis. Hundreds of quadruplex-interactive small molecules have been reported, and the challenges in their design vary with the intended application. Herein, we survey the major achievements on the therapeutic potential of such quadruplex ligands, their mode of binding, effects upon interaction with quadruplexes, and consider the opportunities and challenges for their exploitation in drug discovery.
Cancer is a societal burden demanding innovative approaches. A major problem with the conventional chemotherapeutic agents is their strong toxicity and other side effects due to their poor selectivity. Uncontrolled proliferation of cancer cells is due to mutations, deletions, or amplifications in genes (oncogenes) encoding for proteins that regulate cell growth and division, such as transcription factors, for example, c-MYC. The direct targeting of the c-MYC protein has been attempted but so far unsuccessfully, as it lacks a definite binding site for the modulators. Meanwhile, another approach has been explored since the discovery that G-quadruplex secondary DNA structures formed in the guanine-rich sequences of the c-MYC promoter region can downregulate the transcription of this oncogene. Here, we will overview the major achievements made in the last decades towards the discovery of a new class of anticancer drugs targeting G-quadruplexes in the c-MYC promoter of cancer cells.
The quadruplex DNA structures formed by the guanine-rich sequences (G4) present in promoter regions of oncogenes, like c-MYC, are emerging as selective anticancer drug targets, with two molecules in phase I clinical trials. G4s are dynamic structures regulating several genome processes and being regulated by helicases. Moreover, not only oncogene promoter G4s are increased in cancer cells, but also helicases are overexpressed in these cells, thus making these two genome regulators attractive targets for anticancer intervention. Herein we disclose the structure of a new small molecule with high affinity and selectivity to the cMYCG4 (Kb = 6.7 ± 0.6 x 10^6 M^-1 or KD= 0.15 ± 0.01 µM), capacity to inhibit the activity of the helicase DHX36 with Ki ~ 7 µM and antiproliferative activity in breast cancer cells overexpressing c-MYC, with IC50 values also in the low µM range. Importantly, due to the reduced number of protonable groups, this new inhibitor of DHX36-mediated G4-unfolding activity is a better drug lead molecule than the previously reported ones. The mechanism of action of this compound in breast cancer cells is now being investigated.